Skip to main content

Advanced Clear Cell Renal Cell Carcinoma S2419

Status: Open to Enrollment
Email us to enroll

Study details

View study details on clinicaltrials.gov.

Locations

  • Sutter Health System Wide

Clinical trial FAQs

Information for patients and study volunteers, including frequently asked questions.

Phase III Double Blinded Trial of Immune-Based Therapy With a Live Biotherapeutic MO-03 or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma [BioFront Trial]

Ari D Baron, M.D.
Ari D Baron, M.D.
Principal investigator
View profile

Related clinical trials

View all clinical trials
  • Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma - STRIKE

    Status: Open to Enrollment

  • Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)

    Status: Open to Enrollment

  • A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer

    Status: Open to Enrollment

  • Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    Status: Open to Enrollment

  • A Randomized, Blinded, Placebo-controlled Trial of Shengbai Oral Formula to Assess Safety and Alleviation of Adverse Effects in Patients With Cancer Undergoing Chemotherapy

    Status: Open to Enrollment

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?